Nyxoah Begins U.S. BREATHE Study With First Genio Implant
Mont-Saint-Guibert, Belgium — September 7, 2026 Nyxoah announced that the first patient has been implanted in BREATHE, its U.S....
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Mont-Saint-Guibert, Belgium — September 7, 2026 Nyxoah announced that the first patient has been implanted in BREATHE, its U.S....
Middle East Partnership Advances Neurostimulation Care – February 18, 2026 | Mont-Saint-Guibert, Belgium Nyxoah has signed a Memorandum of...
MONT-SAINT-GUIBERT, Belgium, Oct. 6, 2025 — Nyxoah SA announced that the first U.S. commercial patients have been implanted with...
